GSE120210 GSE120214 TBXT brachyury inhibition 2 v 3 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE120210_GSE120214_TBXT_brachyury inhibition_2_v_3_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE120210_GSE120214_TBXT_brachyury inhibition_2_v_3_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE120210_GSE120214_TBXT_brachyury inhibition_2_v_3_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE120210_GSE120214_TBXT_brachyury inhibition_2_v_3_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

high mobility group box 1 pseudogene 5

Gene

TMPO antisense RNA 1

Gene

MT-ATP6 pseudogene 1

Gene

USP2 antisense RNA 1

Gene

long intergenic non-protein coding RNA 649

Gene

MT-ND4 pseudogene 12

Gene

MT-CO1 pseudogene 12

Gene

ZFHX4 antisense RNA 1

Gene

long intergenic non-protein coding RNA 2762

Gene

HK2 divergent transcript

  • Gene

    high mobility group box 1 pseudogene 5


  • Gene

    TMPO antisense RNA 1


  • Gene

    MT-ATP6 pseudogene 1


  • Gene

    USP2 antisense RNA 1


  • Gene

    long intergenic non-protein coding RNA 649


  • Gene

    MT-ND4 pseudogene 12


  • Gene

    MT-CO1 pseudogene 12


  • Gene

    ZFHX4 antisense RNA 1


  • Gene

    long intergenic non-protein coding RNA 2762


  • Gene

    HK2 divergent transcript

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.